REFERENCES
- Thouvenot É. Update on clinically isolated syndrome. Presse Med(2015) 44(4 Pt 2):e121-36.
doi: 10.1016/j.lpm.2015.03.002.
- Miller DH, Chard DT, Ciccarelli O. Clinically isolated syndromes.Lancet Neurol (2012) 11(2):157-69. doi:
10.1016/S1474-4422(11)70274-5.
- Petržalka M, Meluzínová E, Libertínová J, Mojžišová H, Hanzalová J,
Ročková P. IL-2, IL-6 and chitinase 3-like 2 might predict early
relapse activity in multiple sclerosis. PLoS One (2022)
17(6):e0270607. doi: 10.1371/journal.pone.0270607.
- Deisenhammer F, Zetterberg H, Fitzner B, Zettl UK. The Cerebrospinal
Fluid in Multiple Sclerosis. Front Immunol (2019) 10:726. doi:
10.3389/fimmu.2019.00726.
- Arneth BM. Impact of B cells to the pathophysiology of multiple
sclerosis. J Neuroinflammation (2019) 16(1):128. doi:
10.1186/s12974-019-1517-1.
- Bhargava P, Hartung HP, Calabresi PA. Contribution of B cells to
cortical damage in multiple sclerosis. Brain (2022)
145(10):3363-3373. doi: 10.1093/brain/awac233.
- Alvarez E, Piccio L, Mikesell RJ, Klawiter EC, Parks BJ, Naismith RT,
et al. CXCL13 is a biomarker of inflammation in multiple sclerosis,
neuromyelitis optica, and other neurological conditions. Mult
Scler (2013) 19(9):1204-8. doi: 10.1177/1352458512473362.
- Hartung HP, Aktas O, Menge T, Kieseier CK. Immune regulation of
multiple sclerosis. Handb Clin Neurol (2014) 122:3-14. doi:
10.1016/B978-0-444-52001-2.00001-7.
- Bielekova B, Komori M, Xu Q, Reich DS, Wu T. Cerebrospinal fluid
IL-12p40, CXCL13 and IL-8 as a combinatorial biomarker of active
intrathecal inflammation. Plos One (2012) 7(11):e48370. doi:
10.1371/journal.pone.0048370.
- Matejčíková Z, Mareš J, Přikrylová Vranová H, Klosová J, Sládková V,
Doláková J, et al. Cerebrospinal fluid inflammatory markers in
patients with multiple sclerosis: a pilot study (2015). J Neural
Transm (Vienna) 122(2):273-7. doi: 10.1007/s00702-014-1244-9.
- Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an
expanded disability status scale (EDSS). Neurology (1983)
33(11):1444-52. doi: 10.1212/wnl.33.11.1444.
- Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et
al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the
”McDonald Criteria”. Ann Neurol (2005) 58(6):840-6. doi:
10.1002/ana.20703.
- Baggiolini M, Clark-Lewis I. Interleukin-8, a chemotactic and
inflammatory cytokine. FEBS Lett (1992) 307(1):97-101. doi:
10.1016/0014-5793(92)80909-z.
- Legle DF, Loetscher M, Roos RS, Clark-Lewis I, Baggiolono M, Moser B.
B cell-attracting chemokine 1, a human CXC chemokine expressed in
lymphoid tissues, selectively attracts B lymphocytes via BLR1/CXCR5.J Exp Med (1998) 187(4):655-60. doi: 10.1084/jem.187.4.655.
- Wagner JN, Weis S, Kubasta C, Panholzer J, von Oertzen T.J. CXCL13 as
a diagnostic marker of neuroborreliosis and other neuroinflammatory
disorders in an unselected group of patients. J Neurol (2018)
265, 74-81. doi: 10.1007/s00415-017-8669-7.
- Rupprecht TA, Plate A, Adam M, Wick M, Kastenbauer S, Schmidt C, et
al. The chemokine CXCL13 is a key regulator of B cell recruitment to
the cerebrospinal fluid in acute lyme neuroboreliosis. J
neuroinflammation (2009) 6, 42.
doi: 10.1186/1742-2094-6-42.
- Sapko K, Jamroz-Wiśniewska A, Marciniec M, Kulczyński M,
Szczepańska-Szerej A, Rejdak K. Biomarkers in Multiple Sclerosis: a
review of diagnostic and prognostic factors. Neurol Neurochir
Pol (2020) 54(3):252-258. doi: 10.5603/PJNNS.a2020.0037.
- Bartosik-Psujek H, Stelmasiak Z. The levels of chemokines CXCL8, CCL2
and CCL5 in multiple sclerosis patients are linked to the activity of
the disease. Eur J Neurol (2005) 12(1):49-54. doi:
10.1111/j.1468-1331.2004.00951.x.
- Stelmasiak Z,
Kozioł-Montewka
M, Dobosz B, Rejdak K, Bartosik-Psujek H, Mitosek-Szewczyk K, et al.
Interleukin-6 concentration in serum and cerebrospinal fluid in
multiple sclerosis patients. Med Sci Monit (2000) 6(6):1104-8.
- Matejčíková Z, Mareš J, Sládková V, Svrčinová T, Vysloužilová J,
Zapletalová J, et al. Cerebrospinal fluid and serum levels of
interleukin-8 in patients with multiple sclerosis and its correlation
with Q-albumin. Mult cler Relat Disord (2017) 14:12-15. doi:
10.1016/j.msard.2017.03.007.
- Rossi S, Motta C, Studer V, Macchiarulo G, Germani G, Finardi A, et
al. Subclinical central inflammation is risk for RIS and CIS
conversion to MS. Mult Scler (2015) 21(11):1443-52.
- Khademi M, Kockum I, Andersson ML, Iacobaeus E, Brundin L, Sellebjerg,
F, et al. Cerebrospinal fluid CXCL13 in multiple sclerosis: a
suggestive prognostic marker for the disease course. Mult Scler(2011) 17(3):335-43. doi: 10.1177/1352458510389102.
- Brettschneider J, Czerwoniak A, Senel M, Fang L, Kassubek J, Pinkhardt
E, et al. The chemokine CXCL13 is a prognostic marker in clinically
isolated syndrome (CIS). PLoS One (2010) 5, e11986. doi:
10.1371/journal.pone.0011986.
- Lepennetier G, Hracsko Z, Unger M, Van Griesven M, Grummel V,
Krumbholz M, et al. Cytokine and immune cell profiling in the
cerebrospinal fluid of patients with neuro-inflammatory diseases.J Neuroinflammation (2019) 16(1):219. doi:
10.1186/s12974-019-1601-6.
- Ferraro D, Galli V, Vitetta F, Simone AM, Bedin R, Del Giovane C, et
al. Cerebrospinal fluid CXCL13 in clinically isolated syndrome
patients: Association with oligoclonal IgM bands and prediction of
Multiple Sclerosis diagnosis. J Neuroimmunol (2015) 283:64-9.
doi: 10.1016/j.jneuroim.2015.04.011.
- DiSano KD, Gilli F, Pachner AR. Intrathecally produced CXCL13: A
predictive biomarker in multiple sclerosis. Mult Scler J Exp
Tranl Clin (2020) 6(4). doi: 10.1177/2055217320981396.